Incorporating GLP-1 agonists as part of the postoperative treatment plan can help maintain weight loss and prevent the recurrence of obesity-related comorbidities. They serve as an adjunct tool to support continued appetite control and metabolic health in the long term.
Contrastingly, administration of a GLP-1 agonist often comes with gastrointestinal symptoms as side effects such as nausea, vomiting. GLP-1 agonists not only show a significant ability to decrease weight loss, they can also improve obesity-related comorbidities.
Additionally, GLP-1 RAs may provide benefits for other obesity-related comorbidities, including hypertension and cardiovascular disease, which are commonly associated with OSA. The future integration of GLP-1 RAs into OSA treatment protocols could mark a paradigm shift...
When determining the best approach for treating obesity, whole health is a major consideration. Comorbidities, the environment, behavioral or mental health factors, and medication side effects (which can worsen the condition) can all play a role in achieving weight objectives.
7. American Diabetes Association Professional Practice Committee. Obesity and weight management for the prevention and treatment of type 2 diabetes: Standards of Care in Diabetes2025.Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment.
What Are the Medical Treatments for Obesity? Pharmacotherapy for obesity advanced substantially with GLP-1 receptor agonists. GLP-1 is the most meaningful development in obesity medicine since bariatric surgery itself.
